Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 701–800 of 1,002
Gillis, J. L., Selth, L. A., Centenera, M. M., Townley, S. L., Sun, S., Plymate, S. R., Tilley, W. D., & Butler, L. M. (2013) · Oncotarget · doi:10.18632/oncotarget.975 · Cited by 61
“The totality of research in this field has demonstrated that CRPC is characterized by sustained androgen receptor (AR) signaling within the “castrate” environment [1] through adaptive mechanisms such as increased intratumoral androgen biosynthesis [2], AR overexpression and amplification [3, 4] and increased response…”
BackgroundCrnalic, S., Hörnberg, E., Wikström, P., Lerner, U. H., Tieva, Å., Svensson, O., Widmark, A., & Bergh, A. R. J. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0059 · Cited by 62
Terry, S., Maillé, P., Baaddi, H., Kheuang, L., Soyeux, P., Nicolaïew, N., Céraline, J., Firlej, V., Beltran, H., Allory, Y., et al. (2013) · Neoplasia · doi:10.1593/neo.122070 · Cited by 66
“It is also tempting to speculate that %$%" AR plays a crucial role in this potential molecular switch as AR is consistently implicated %$&" in the growth of castrate resistant tumors [41, 46].”
Dryhurst, D. D., McMullen, B., Fazli, L., Rennie, P. S., & Ausió, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.003 · Cited by 68
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment
Ferroni, C., Pepe, A., Kim, Y. S., Lee, S., Guerrini, A., Parenti, M. D., Tesei, A., Zamagni, A., Cortesi, M., Zaffaroni, N., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00105 · Cited by 66
Terada, N., Maughan, B. L., Akamatsu, S., Kobayashi, T., Yamasaki, T., Inoue, T., Kamba, T., Ogawa, O., & Antonarakis, E. S. (2017) · International Journal of Urology · doi:10.1111/iju.13346 · Cited by 58
The Genomics of Prostate Cancer: emerging understanding with technologic advances
Rubin, M. A., & Demichelis, F. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.166 · Cited by 63
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
McDevitt, M. R., Thorek, D. L. J., Hashimoto, T., Gondo, T., Veach, D. R., Sharma, S. K., Kalidindi, T. M., Abou, D. S., Watson, P. A., Beattie, B. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04107-w · Cited by 59
Kokontis, J. M., Hsu, S., Chuu, C., Dang, M. T., Fukuchi, J., Hiipakka, R. A., & Liao, S. (2005) · The Prostate · doi:10.1002/pros.20285 · Cited by 58
“[16] who reported agonistic effects of Casodex in androgen-independent LNCaP cells.”
BackgroundDiscovery of Novel Androgen Receptor Ligands by Structure-Based Virtual Screening and Bioassays
Zhou, W., Duan, M., Fu, W., Pang, J., Tang, Q., Sun, H., Xu, L., Chang, S., Li, D., & Hou, T. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.03.007 · Cited by 58
“It has been reported that AR gene and protein are both generally overexpressed at late stage of PCa [5,6].”
BackgroundMarchiani, S., Tamburrino, L., Nesi, G., Paglierani, M., Gelmini, S., Orlando, C., Maggi, M., Forti, G., & Baldi, E. (2010) · International Journal of Andrology · doi:10.1111/j.1365-2605.2009.01030.x · Cited by 64
MicroRNA‐135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth
Aakula, A., Leivonen, S., Hintsanen, P., Aittokallio, T. A., Ceder, Y., Børresen‐Dale, A., Perälä, M., Östling, P., & Kallioniemi, O. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.001 · Cited by 61
Loberg, R. D., McGregor, N., Chi, Y., Sargent, E., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07778 · Cited by 57
“Multiple mechanisms have been identified that contribute to the transition to the androgen-independent phenotype [13–17].”
BackgroundCancer Stem Cells in Prostate Cancer Chemoresistance
Ni, J., Cozzi, P. J., Hao, J., Duan, W., Graham, P., Kearsley, J. H., & Li, Y. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140328152459 · Cited by 62
“Many possible mechanisms have been advocated to explain the etiology of CRPC, most of which centre on AR amplification [139], AR overexpression [140], AR mutations [141] and AR-independent and survival pathways upregulation [142].”
BackgroundLamb, L. E., Zarif, J. C., & Miranti, C. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2745 · Cited by 66
Knudsen, K. E., & Kelly, W. K. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.33 · Cited by 67
DaSilva, J. O., Gioeli, D. G., Weber, M. J., & Parsons, S. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4687 · Cited by 58
“Increases in AR are both necessary and sufficient to convert prostate cancer cells from a hormone-sensitive to a hormonerefractory state (3).”
BackgroundPlymate, S. R., Haugk, K. H., Coleman, I. M., Woodke, L. B., Vessella, R. L., Nelson, P. S., Montgomery, B., Ludwig, D. L., & Wu, J. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0648 · Cited by 61
Self-citationCholine Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
Asim, M., Massie, C. E., Orafidiya, F. A., Pértega‐Gomes, N., Warren, A. Y., Esmaeili, M., Selth, L. A., Zecchini, H. I., Luko, K., Qureshi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv371 · Cited by 60
“The androgen receptor (AR) is a ligand-inducible transcription factor of the nuclear hormone receptor superfamily that plays a critical role in tumor initiation, growth, and progression of PCa (2,3).”
BackgroundSato, S., Katsushima, K., Shinjo, K., Hatanaka, A., Ohka, F., Suzuki, S., Naiki‐Ito, A., Soga, N., Takahashi, S., & Kondo, Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3339 · Cited by 62
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
Norris, J. D., Miner, S. J., Baker, J. G., Stagg, D. B., Wardell, S. E., Park, S. H., Alley, H. M., Baldi, R. M., Yllanes, A. P., Andreano, K. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87328 · Cited by 57
Compagno, D., Arnold, C., Morin, A., Gilbert, C., Mathieu, J. R. R., Bözec, A., Mauduit, C., Benahmed, M., & Cabon, F. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001006 · Cited by 68
“In experimental tumors, a moderate overexpression of AR in androgen-dependent tumors allows experimental tumors bypassing hormone ablation [6].”
BackgroundMethodInfluentialMolecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway
Mellado, B., Codony, J., Ribal, M. J., Visa, L., & Gascón, P. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0304-3 · Cited by 63
“In in vitro studies, AR inhibition in androgen-independent cell lines inhibited tumour growth [22, 23].”
BackgroundLi, X., Wang, Y., Deng, S., Zhu, G., Wang, C., Johnson, N. A., Zhang, Z., Tirado, C. R., Xu, Y., Metang, L. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.010 · Cited by 69
Caboni, L., Kinsella, G. K., Blanco, F., Fayne, D., Jagoe, W. N., Carr, M. J., Williams, D. C., Meegan, M. J., & Lloyd, D. G. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201438f · Cited by 56
Kruczek, K. R., Ratterman, M., Tolzien, K., SULO, S. S., Lestingi, T. M., & Nabhan, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.530 · Cited by 61
“(Debes and Tindall, 2004) These have been generally divided into pathways dependent on the androgen receptor (AR) and others that are activated independent of the AR (Chen et al, 2004).”
BackgroundWu, K., Gore, C., Yang, L., Fazli, L., Gleave, M. E., Pong, R.-C., Xiao, G., Zhang, L., Yun, E.-J., Tseng, S.-F., et al. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1360 · Cited by 60
Roell, D., & Baniahmad, A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.09.013 · Cited by 60
Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium
Lim, M. A., Otto‐Duessel, M., He, M., Su, L., Nguyen, D., Chin, E., Alliston, T. N., & Jones, J. O. (2014) · ACS Chemical Biology · doi:10.1021/cb400759d · Cited by 58
Takayama, K., Horie‐Inoue, K., Ikeda, K., Urano, T., Murakami, K., Hayashizaki, Y., Ouchi, Y., & Inoue, S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.056 · Cited by 58
Hedgehog Signalling in Androgen Independent Prostate Cancer
Shaw, G. L., Price, A. M., Ktori, E., Bisson, I., Purkis, P. E., McFaul, S., Oliver, R. T. D., & Prowse, D. M. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.070 · Cited by 56
Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update
Mackinnon, A. C., Yan, B. C., Joseph, L. J., & Al‐Ahmadie, H. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.7.1033 · Cited by 61
Bhattacharyya, R. S., Krishnan, A. V., Swami, S., & Feldman, D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0065 · Cited by 64
“(31, 32), and some AIPC patients express up to 70-fold higher levels of AR mRNA and increased AR protein compared with primary prostate cancer patients (31, 33).”
BackgroundWare, K. E., Somarelli, J. A., Schaeffer, D., Li, J., Zhang, T., Park, S., Patierno, S. R., Freedman, J. A., Foo, W., García-Blanco, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10476 · Cited by 59
“During CRPC progression and resistance to hormonaltargeted therapies, continued dependence on the AR is a common occurrence, and sustained activation of the AR transcriptional program is observed [3, 4].”
BackgroundAndrogen receptor plasticity and its implications for prostate cancer therapy
Snow, O., Lallous, N., Singh, K., Lack, N. A., Rennie, P. S., & Cherkasov, A. R. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.001 · Cited by 58
Androgen Receptor Binding Sites Identified by a GREF_GATA Model
Masuda, K., Werner, T., Maheshwari, S., Frisch, M., Oh, S., Petrovics, G., May, K., Srikantan, V., Srivastava, S. K., & Dobi, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.009 · Cited by 56
“Androgens and their receptor are the main therapeutic targets in prostate cancer.(25) While androgen blockade has been a significant therapeutic choice,(26) failure of androgen-blockade therapy can dramatically reduce the survival rate.”
BackgroundAndrogen receptor amplification is associated with increased cell proliferation in prostate cancer☆
Haapala, K., Kuukasjärvi, T., HYYTINEN, E.-R., Rantala, I. S., Helin, H., & Koivisto, P. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.09.008 · Cited by 61
“This change was associated with alterations in the recruitment of coactivators and corepressors to the promoters of AR target genes [4].”
BackgroundAbiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, E. A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s39318 · Cited by 63
Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van IJcken, W. F. J., van Weerden, W. M., & Jenster, G. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023144 · Cited by 56
“have shown that AR overexpression is the most common modification following androgen ablation treatment, and is sufficient to confer hormonal therapy-refractory growth [33].”
BackgroundSchayowitz, A., Sabnis, G. J., Njar, V. C. O., & Brodie, A. M. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0581 · Cited by 56
Twiddy, A. L., Cox, M., & Wasan, K. M. (2011) · The Prostate · doi:10.1002/pros.21499 · Cited by 58
Takayama, K., Horie‐Inoue, K., SUZUKI, T. A., Urano, T., Ikeda, K., Fujimura, T., Takahashi, S., Homma, Y., Ouchi, Y., & Inoue, S. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1242 · Cited by 59
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance
Zarif, J. C., & Miranti, C. K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.013 · Cited by 62
“For AR, the PXXP sequences within the AR linker domain mediate binding through the Src SH3 domain [5, 14, 128].”
Schwartzberg, L. S., Yardley, D. A., ELIAS, A. D., Patel, M. R., LoRusso, P. M., Burris, H. A., Gucalp, A., Peterson, A., Blaney, M. E., Steinberg, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2339 · Cited by 55
“Constipation 1 (3) 2 (10) 1 (6) 2 (9) 2 (18) 7 (10)”
BackgroundMaximal androgen blockade for advanced prostate cancer
Klotz, L. H. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.004 · Cited by 59
STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
Wang, L., Jin, Y., Arnoldussen, Y. J., Jonson, I., Qu, S., Mælandsmo, G. M., Kristian, A., Risberg, B., Wæhre, H., Danielsen, H. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4697 · Cited by 53
“It should be pointed out that PC3 and DU145 cells lack a functional AR that is present in the majority of advanced, relapsed prostate cancers (31); thus, these two cell lines are not the best models for advanced, androgen-independent prostate cancer.”
BackgroundHan, D. G., Labaf, M., Zhao, Y., Owiredu, J. N., Zhang, S., Patel, K. J., Venkataramani, K., Steinfeld, J. S., Han, W., Li, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci168649 · Cited by 63
Rao, S., Lyons, L. S., Fahrenholtz, C. D., Wu, F., Farooq, A., Balkan, W., & Burnstein, K. L. (2011) · Oncogene · doi:10.1038/onc.2011.273 · Cited by 57
“As AR signaling is critical in prostate cancer progression to castration resistance (Chen et al., 2004), targeting the AR remains a major therapeutic strategy for advanced prostate cancer.”
BackgroundMüller, S., Holzapfel, K., Seidl, C., Treiber, U., Krause, B. J., & Senekowitsch–Schmidtke, R. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1117-x · Cited by 63
“In many patients there is tumour progression from a slow-growing, androgen-dependent carcinoma toward a more and more aggressive, androgen-independent tumour [3, 4].”
BackgroundMediwala, S. N., Sun, H., Szafran, A. T., Hartig, S. M., Sonpavde, G., Hayes, T. G., Thiagarajan, P., Mancini, M. A., & Marcelli, M. (2012) · The Prostate · doi:10.1002/pros.22566 · Cited by 60
“with CRPC have been androgen depleted by chemical or surgical castration, their androgen receptor (AR) signaling remains active and appears necessary to drive tumor growth [2,3].”
BackgroundLupold, S. E., & Kumar, B. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.177839 · Cited by 56
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
Graham, L. S., & Schweizer, M. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0759-3 · Cited by 56
Mechanisms of antiprostate cancer by gum mastic: NF-?B signal as target
He, M., Li, A., Chun-su, X. U., Shun-li, W. A. N. G., ZHANG, M.-J., Gu, H., Yang, Y., & Tao, H. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00536.x · Cited by 54
Alvarado, C., Beitel, L. K., Sircar, K., Aprikian, A. G., Trifiro, M. A., & Gottlieb, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0399 · Cited by 55
“Initially, it was assumed that the AR would play no role in androgen resistance; however, recent studies have noted that an increase in AR mRNA and protein seems to be both necessary and sufficient to convert prostate cancer growth from a hormonesensitive to a hormone-independent state (30, 31).”
BackgroundThe evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model
Eikenberry, S. E., Nagy, J. D., & Kuang, Y. (2010) · Biology Direct · doi:10.1186/1745-6150-5-24 · Cited by 62
“[30] found that in 7 prostate cancer xenograft models, increased androgen receptor expression was the only change consistently associated with HR cancer progression.”
BackgroundInfluentialTargeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 67
“Advanced prostate cancer is a heterogenous disease with a multitude of primary and acquired treatment resistance mechanisms [30,31].”
BackgroundDing, M., Lin, B., Li, T., Liu, Y., Li, Y., Zhou, X., Miao, M., Gu, J., Pan, H., Yang, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3480 · Cited by 58
“Although androgen deprivation treatment (ADT) has been proven effectively to suppress the tumor growth and progression of androgensensitive PCa, most of those androgen-sensitive PCa will eventually develop the resistance to ADT and become castration-resistant prostate cancer (CRPC), in which upregulation of androgen s…”
BackgroundDownregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype
Roy, S., Singh, R. P., Agarwal, C., Siriwardana, S., Sclafani, R. A., & Agarwal, R. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6024 · Cited by 53
“The doubling time of the cells was calculated using the formula: ‘h*ln(2)/ln(c2/c1)’ where h is the time difference; c1 is the initial cell number; c2 is the final cell number after h hours.”
MethodHistone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth
Jääskeläinen, T. J., Makkonen, H., Visakorpi, T., Kim, J., Roeder, R. G., & Palvimo, J. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.11.025 · Cited by 59
Matei, D. V., Renne, G., Pimentel, M., Sandri, M. T., Zorzino, L., Botteri, E., Cicco, C. D., Musi, G., Brescia, A., Mazzoleni, F., et al. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2011.12.004 · Cited by 53
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells
Li, T.-H., Zhao, H., Peng, Y., Beliakoff, J., Brooks, J. D., & Sun, Z. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm198 · Cited by 57
“Increasing cellular levels of the AR not only enhances androgen-induced cell growth but increases the sensitivity of prostate cancer cells to androgens, allowing the tumor cells to grow in a low androgen environment (31).”
BackgroundAttard, G., & Bono, J. S. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0943 · Cited by 56
Obinata, D., Takayama, K., Fujiwara, K., Suzuki, T., Tsutsumi, S., Fukuda, N., Nagase, H., Fujimura, T., Urano, T., Homma, Y., et al. (2016) · Oncogene · doi:10.1038/onc.2016.171 · Cited by 49
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
Bakrania, A. K., Variya, B. C., & Patel, S. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.023 · Cited by 57
Xu, Y.-M., Wijeratne, E. M. K., Babyak, A. L., Marks, H., Brooks, A. D., Tewary, P., Xuan, L., Wang, W.-Q., Sayers, T. J., & Gunatilaka, A. A. L. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b01129 · Cited by 53
Niu, Y., Guo, C., Wen, S., Tian, J., Luo, J., Wang, K., Tian, H., Yeh, S., & Chang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.020 · Cited by 61
Serritella, A. V., Shevrin, D., Heath, E. I., Wade, J. L., Martinez, E., Anderson, A. K. L., Schonhoft, J. D., Chu, Y.-L., Karrison, T., Stadler, W. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4049 · Cited by 59
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Markowski, M. C., Taplin, M., Aggarwal, R. R., Sena, L. A., Wang, H., Qi, H., Lalji, A., Sinibaldi, V. J., Carducci, M. A., Paller, C. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44514-2 · Cited by 62
Makkonen, H., Kauhanen, M., Jääskeläinen, T. J., & Palvimo, J. J. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.08.008 · Cited by 56
“Unfortunately, overexpression of AR may convert the bicalutamide (that is under normal cells considered a pure antagonist) to an agonist (Chen et al., 2004).”
BackgroundMethodTavassoli, P., Wafa, L. A., Cheng, H., Zoubeidi, A., Fazli, L., Gleave, M. E., Snoek, R., & Rennie, P. S. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0229 · Cited by 56
Mutations in the AXIN1 Gene in Advanced Prostate Cancer
Yardy, G., Bicknell, D., Wilding, J. L., Bartlett, S., Liu, Y., WINNEY, B. J., Turner, G. D. H., BREWSTER, S. F., & Bodmer, W. F. (2008) · European Urology · doi:10.1016/j.eururo.2008.05.029 · Cited by 55
Zhu, M., Partin, J. V., Bruckheimer, E. M., Strup, S. E., & Kyprianou, N. (2007) · The Prostate · doi:10.1002/pros.20698 · Cited by 53
“Indeed, increased AR levels can confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand [5].”
BackgroundTargeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC)
Tsao, C., Galsky, M. D., Small, A., Yee, T., & Oh, W. K. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11445.x · Cited by 60
Hsp90: Still a viable target in prostate cancer
Centenera, M. M., Fitzpatrick, A. K., Tilley, W. D., & Butler, L. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.005 · Cited by 53
Khaja, A. S. S., Helczynski, L., Edsjö, A., Ehrnström, R. A., Lindgren, A., Ulmert, D., Andersson, T., & Bjartell, A. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026539 · Cited by 52
“The molecular mechanisms responsible for transition into CRPC are poorly understood, however, the most consistent change associated with castration-resistant growth in global gene expression profiles of PCa xenografts was an increase in the AR mRNA levels [4].”
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
Persson, J. L., Semenas, & Dizeyi (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45703 · Cited by 61
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Lee, E., Ha, S., & Logan, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141589 · Cited by 53
“LNCaP cells cultured in hormone-deprived media were growth arrested as expected [39] but GSK-3 inhibitor treatment or APC knockdown induced growth similar to DHT treatment (Fig 4A and 4E).”
BackgroundCai, C., Portnoy, D. C., Wang, H., Jiang, X., Chen, S., & Balk, S. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0026 · Cited by 57
Prevention of Prostate Cancer by Androgens: Experimental Paradox or Clinical Reality
Algarté-Génin, M., Cussenot, O., & Costa, P. (2004) · European Urology · doi:10.1016/j.eururo.2004.04.012 · Cited by 58
Cao, R., Ke, M., Wu, Q., Tian, Q., Liu, L., Dai, Z., Lu, S., & Liu, P. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28366 · Cited by 51
Xu, Y., Yang, Y., Wang, Z., Sjöström, M., Jiang, Y., Tang, Y., Cheng, S., Deng, S., Wang, C., Gonzalez, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0539 · Cited by 50
“…the effect of ZNF397-KO in AR-targeted therapy resistance in vivo , we first examined the well-characterized LNCaP/AR xenograft model, which exhibits AR amplification (compared to LNCaP cells) and parallels the clinical progression of patients with mCRPC characterized by aberrant AR signaling (47).”
Shen, H. C., & Balk, S. P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.005 · Cited by 57
“In a previous study, the Sawyers lab found that overexpression of exogenous AR alone could render PC xenografts resistant to castration and to bicalutamide, which gained partial agonist activity in AR-overexpressing cells (Chen et al., 2004).”
BackgroundAdvances in mouse models of prostate cancer
Ahmad, I., Sansom, O. J., & Leung, H. Y. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000689 · Cited by 56
Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis
Liu, Y.-N., Yin, J., Barrett, B., Sheppard-Tillman, H., Li, D., Casey, O. M., Fang, L., Hynes, P. G., Ameri, A. H., & Kelly, K. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00008-15 · Cited by 49
“We used three human cell models to address AR-initiated regulation of miR-1: inducible AR expression in the AR-negative DU145 cells, endogenously AR-positive LNCaP, and highly ARexpressing LNCaP-AR (37).”
MethodEfficacy of c-Met inhibitor for advanced prostate cancer
Tu, W. H., Zhu, C., Clark, C. J., Christensen, J. G., & Sun, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-556 · Cited by 55
“AR is still expressed in most CRPC and plays a critical role during disease progression [3,4,27,28].”
Altintas, D. M., Shukla, M. S., Goutte-Gattat, D., Angelov, D., Rouault, J., Dimitrov, S. I., & Samarut, J. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1016 · Cited by 54
“When activated by androgens, AR regulates gene transcription (1).”
BackgroundArmstrong, A. J., & Febbo, P. G. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0043 · Cited by 51
Targeted therapy of cancer: new roles for pathologists—prostate cancer
Rubin, M. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.11 · Cited by 57
Inoue, T., Yoshida, T., Shimizu, Y., Kobayashi, T., Yamasaki, T., Toda, Y., Segawa, T., Kamoto, T., Nakamura, E., & Ogawa, O. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0033 · Cited by 52
“Growing evidence suggests that AR plays an essential role in transition of androgen-independent cell proliferation in prostate cancer (3).”
BackgroundResultYang, C.-C., Wang, Y.-C., Wei, S., Lin, L.-F., Chen, C., Lee, C.-C., Lin, C., & Chen, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2759 · Cited by 50
Self-citationMechanisms Leading to the Development of Hormone-Resistant Prostate Cancer
Kasper, S., & Cookson, M. S. (2006) · Urologic Clinics of North America · doi:10.1016/j.ucl.2005.12.010 · Cited by 51
Bu, H., Schweiger, M. R., Manke, T., Wunderlich, A., Timmermann, B., Kerick, M., Pasqualini, L., Shehu, E., Fuchsberger, C., Cato, A. C. B., et al. (2013) · FEBS Journal · doi:10.1111/febs.12118 · Cited by 54
Takahashi, S., Watanabe, T., Okada, M., Inoue, K., Ueda, T., Takada, I., Watabe, T., Yamamoto, Y., Fukuda, T., Nakamura, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014850108 · Cited by 53
“Moreover, AR is considered a key factor in prostate cancer even after transition to the androgen-independent state (16, 38).”
BackgroundFactors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate Cancer
Bonkhoff, H. (2011) · Prostate Cancer · doi:10.1155/2012/593241 · Cited by 54
“This hypersensitive pathway has been recognized as a major determinant for the development of CRPCa by maintaining AR signaling during standard ADT [19].”
BackgroundHu, R., Denmeade, S. R., & Luo, J. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.49 · Cited by 61
Saraç, H., Morova, T., Pires, E., McCullagh, J., Kaplan, A., Cingöz, A., Onder, T. B., Önder, T. T., Kawamura, A., & Lack, N. A. (2019) · Oncogene · doi:10.1038/s41388-019-1116-8 · Cited by 53
Fujimoto, N., Miyamoto, H., Mizokami, A., Harada, S., Nomura, M. J., Ueta, Y., Sasaguri, T., & Matsumoto, T. (2007) · Cancer Investigation · doi:10.1080/07357900601130698 · Cited by 49
“(12) demonstrated that AR-overexpressed prostate cancer cells become androgenhypersensitive and that a modest increase in the AR concentration permitted the AR to function despite the presence of lower levels of androgen.”
BackgroundRegulation of Androgen-Responsive Transcription by the Chromatin Remodeling Factor CHD8
Menon, T., Yates, J. A., & Bochar, D. A. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0421 · Cited by 49
Li, J., & Coetzee, G. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3679 · Cited by 53
“It was recently shown that increased androgen receptor expression levels are necessary and sufficient to convert prostate cancer to an ablation-resistant state (17).”
Background
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.